Patient characteristics for those who survived and event-free at least 1 year after the first allogeneic transplant
| Risk factor . | N (%) . |
|---|---|
| Sex | |
| Male | 2814 (57.4) |
| Female | 2091 (42.6) |
| Race | |
| White | 4276 (91.8) |
| Other | 383 (8.2) |
| Age at first allogeneic HCT, y | |
| ≤20 | 1162 (23.7) |
| >20-50 | 2684 (54.7) |
| >50 | 1059 (21.6) |
| HCT diagnosis category | |
| Nonmalignant diseases | 405 (8.3) |
| Hematologic malignancies | 4500 (91.7) |
| Preparative regimen | |
| Chemotherapy only | 1544 (31.6) |
| Low-dose TBI 200-450 cGy | 775 (15.8) |
| Single-fraction TBI 600-1000 cGy | 168 (3.4) |
| Fractionated TBI 600-1200* cGy | 1157 (23.6) |
| Fractionated TBI 1320-1400 cGy | 680 (13.9) |
| Fractionated TBI 1440-1750 cGy | 570 (11.7) |
| Stem cell source | |
| BM | 3184 (64.9) |
| PBSC/BM+PBSC | 1584 (32.3) |
| Cord blood | 137 (2.8) |
| GVHD status before event | |
| None | 856 (18.2) |
| Acute only | 951 (20.2) |
| Chronic only | 752 (16.0) |
| Both acute and chronic | 2157 (45.7) |
| Events after 1 y | |
| In follow-up or subsequent transplant | 3037 (61.9) |
| SMN | 499 (10.2) |
| Death without SMN | 1369 (27.9) |
| Age at first SMN after 1 y, y; categorized, n = 499 | |
| ≤20 | 94 (18.8) |
| >20-50 | 286 (57.3) |
| >50 | 119 (23.9) |
| Year of HCT, 15-y increments | |
| ≤1985 | 759 (15.5) |
| 1986-2000 | 2241 (45.7) |
| ≥2001 | 1905 (38.8) |
| Time between first allogeneic HCT and first SMN, y | |
| ≤10 y since transplant | 123 (24.7) |
| 10.1-20 y since transplant | 189 (37.9) |
| 20.1+ y since transplant | 187 (37.5) |
| Risk factor . | N (%) . |
|---|---|
| Sex | |
| Male | 2814 (57.4) |
| Female | 2091 (42.6) |
| Race | |
| White | 4276 (91.8) |
| Other | 383 (8.2) |
| Age at first allogeneic HCT, y | |
| ≤20 | 1162 (23.7) |
| >20-50 | 2684 (54.7) |
| >50 | 1059 (21.6) |
| HCT diagnosis category | |
| Nonmalignant diseases | 405 (8.3) |
| Hematologic malignancies | 4500 (91.7) |
| Preparative regimen | |
| Chemotherapy only | 1544 (31.6) |
| Low-dose TBI 200-450 cGy | 775 (15.8) |
| Single-fraction TBI 600-1000 cGy | 168 (3.4) |
| Fractionated TBI 600-1200* cGy | 1157 (23.6) |
| Fractionated TBI 1320-1400 cGy | 680 (13.9) |
| Fractionated TBI 1440-1750 cGy | 570 (11.7) |
| Stem cell source | |
| BM | 3184 (64.9) |
| PBSC/BM+PBSC | 1584 (32.3) |
| Cord blood | 137 (2.8) |
| GVHD status before event | |
| None | 856 (18.2) |
| Acute only | 951 (20.2) |
| Chronic only | 752 (16.0) |
| Both acute and chronic | 2157 (45.7) |
| Events after 1 y | |
| In follow-up or subsequent transplant | 3037 (61.9) |
| SMN | 499 (10.2) |
| Death without SMN | 1369 (27.9) |
| Age at first SMN after 1 y, y; categorized, n = 499 | |
| ≤20 | 94 (18.8) |
| >20-50 | 286 (57.3) |
| >50 | 119 (23.9) |
| Year of HCT, 15-y increments | |
| ≤1985 | 759 (15.5) |
| 1986-2000 | 2241 (45.7) |
| ≥2001 | 1905 (38.8) |
| Time between first allogeneic HCT and first SMN, y | |
| ≤10 y since transplant | 123 (24.7) |
| 10.1-20 y since transplant | 189 (37.9) |
| 20.1+ y since transplant | 187 (37.5) |
98.4% received dose of 1200 cGy.